CLOs on the Move

InterVenn

www.intervenn.com

 
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.intervenn.com
  • 2 Tower Place 5th Floor
    South San Francisco, CA USA 94080
  • Phone: 888.706.1670

Executives

Name Title Contact Details
Stephana Patton
Chief Legal and Compliance Officer Profile

Similar Companies

4C Medical Technologies

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).

pangenex

pangenex is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChipCare

ChipCare is a Toronto based start-up company developing a point of care blood testing platform for the global health market. The Company`s diagnostic platform is extremely mobile, simple to use, inexpensive and produces laboratory quality results. From single drops of blood, health workers in remote locations can rapidly and accurately perform tests to diagnose or monitor a range of infectious and non-communicable diseases.

Nautilus Environmental

Nautilus Environmental is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.